Zimmer Biomet stock (US98956P1021): knee implant maker in focus after recent earnings

Zimmer Biomet stock is drawing renewed attention from healthcare-focused investors after the orthopedic specialist reported its most recent quarterly results, updated its outlook and commented on procedure demand trends across key markets.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

Zimmer Biomet: core business model

Zimmer Biomet focuses on designing and manufacturing orthopedic implants, surgical instruments and digital technologies that are used by hospitals and surgeons worldwide. The company’s portfolio spans knee and hip replacement systems, extremities, sports medicine products, trauma and craniomaxillofacial solutions as well as related biologics and cement technologies.

The group’s business model is built on close relationships with orthopedic surgeons and hospital systems, with a strong emphasis on clinical data, product reliability and training. In practice, Zimmer Biomet generates recurring revenue as aging populations and active lifestyles drive demand for joint replacement surgeries, while newer robotic and digital platforms aim to support more precise procedures and post-surgery care.

Revenue is typically divided into categories such as knees, hips, S.E.T. (sports medicine, extremities, trauma), craniomaxillofacial and thoracic, spine and dental, along with emerging technology offerings. The company’s geographic footprint includes the United States, Europe and other international regions, with the US market remaining a key profit contributor and a central focus for many investors who follow large-cap medical device stocks.

Main revenue and product drivers for Zimmer Biomet

One of the most important revenue pillars for Zimmer Biomet is its knee replacement franchise. Hospitals and ambulatory surgery centers use the company’s implants and instruments in total and partial knee procedures, which are often driven by demographic factors such as population aging, obesity rates and patient expectations for mobility. The product range includes cemented and cementless systems and is often paired with navigation tools and planning software.

Hip implants are another core contributor, with systems designed for primary and revision procedures. Surgeons can choose from a variety of stems, cups and bearing surfaces depending on patient needs. Over time, incremental innovation – such as new materials, optimized geometries and improved surgical workflows – has been a key part of how Zimmer Biomet competes with other major orthopedic players in the global market.

Beyond large joints, S.E.T. and related businesses add diversification. Sports medicine products serve procedures such as ligament repair and shoulder stabilization, while extremities offerings cover smaller joints like ankles and shoulders. Trauma and craniomaxillofacial products are used in fracture fixation and reconstructive surgery. Dental and spine portfolios further broaden the addressable market, though these areas may follow different capital cycles and reimbursement dynamics compared with knee and hip implants.

Why Zimmer Biomet matters for US investors

For US investors, Zimmer Biomet is part of the group of major medical technology names that benefit from long-term structural trends in healthcare, including the aging baby-boomer generation and the growing acceptance of elective joint replacement at younger ages. As a New York Stock Exchange–listed company trading in US dollars, the stock is accessible to a wide range of retail portfolios and is often included in healthcare or medtech-focused strategies.

The company’s results are closely tied to procedure volumes in US hospitals and ambulatory surgery centers. Any changes in reimbursement, staffing levels or patient willingness to undergo elective procedures can affect quarterly performance. At the same time, innovation in robotics, navigation and data-driven care pathways has the potential to influence Zimmer Biomet’s competitive positioning and margin profile over the medium term.

Conclusion

Zimmer Biomet remains a key player in the global orthopedic implant market, with core businesses in knees and hips that are supported by demographic trends and ongoing innovation. For US investors, the stock offers exposure to procedure-driven growth but also to the operational and regulatory risks inherent in medical technology. How the company executes on product launches, manages costs and navigates hospital spending patterns is likely to remain central for the stock’s long-term narrative.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.